TY - JOUR
T1 - Toward understanding the structural basis of partial agonism at the dopamine D3 receptor
AU - Michino, Mayako
AU - Boateng, Comfort A.
AU - Donthamsetti, Prashant
AU - Yano, Hideaki
AU - Bakare, Oluyomi M.
AU - Bonifazi, Alessandro
AU - Ellenberger, Michael P.
AU - Keck, Thomas M.
AU - Kumar, Vivek
AU - Zhu, Clare
AU - Verma, Ravi
AU - Deschamps, Jeffrey R.
AU - Javitch, Jonathan A.
AU - Newman, Amy Hauck
AU - Shi, Lei
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2017/1/26
Y1 - 2017/1/26
N2 - Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders. In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions. Here, we report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious. To investigate the structural basis of partial agonism, we performed comparative microsecond-scale molecular dynamics simulations starting from the inactive state of D3R in complex with these enantiomers. Analysis of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations. These receptor models bound with partial agonists may be useful for structure-based design of compounds with tailored efficacy profiles.
AB - Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders. In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions. Here, we report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious. To investigate the structural basis of partial agonism, we performed comparative microsecond-scale molecular dynamics simulations starting from the inactive state of D3R in complex with these enantiomers. Analysis of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations. These receptor models bound with partial agonists may be useful for structure-based design of compounds with tailored efficacy profiles.
UR - http://www.scopus.com/inward/record.url?scp=85010664381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010664381&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.6b01148
DO - 10.1021/acs.jmedchem.6b01148
M3 - Article
C2 - 27983845
AN - SCOPUS:85010664381
SN - 0022-2623
VL - 60
SP - 580
EP - 593
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 2
ER -